Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

2.696 -0.074 (-2.66%)
Streaming Delayed Price Updated: 1:26 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectar Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Cellectar Announces Plan to Explore Strategic Alternatives
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Preview For Cellectar Biosciences ↗
 
Via Benzinga
News headline image
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 13, 2025 ↗
 
Via Benzinga
News headline image
Cellectar Biosciences to Present at the 37th Annual Roth Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast ↗
 
Via Benzinga
News headline image
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options ↗
Due to FDA communications, Cellectar Biosciences will explore options for development of its cancer drug. Focus on isotopes for solid tumors. 
Via Benzinga
News headline image
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations ↗
 
Via Benzinga
Topics Economy
News headline image
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 18, 2024 ↗
 
Via Benzinga
News headline image
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Gold Moves Higher; Coca-Cola Increases FY24 Forecast ↗
 
Via Benzinga
News headline image
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 2%; GE Aerospace Earnings Top Views ↗
 
Via Benzinga
News headline image
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study ↗
Cellectar Biosciences stock drops 19.2% following the release of CLOVER WaM study results. The pivotal study for iopofosine I 131 in relapsed/refractory Waldenstrom's macroglobulinemia showed an 80%... 
Via Benzinga
News headline image
CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024 ↗
CLRB stock results show that Cellectar Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50% ↗
Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains. 
Via InvestorPlace
News headline image
Why Is Gamida Cell (GMDA) Stock Down 82% Today? ↗
Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private. 
Via InvestorPlace
News headline image
CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023 ↗
CLRB stock results show that Cellectar Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 27, 2024 ↗
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
News headline image
Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why ↗
Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, achieving 64% complete remission and 73% overall response rate. Roth Capital... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.